Clinical trial · Interventional
LAL-BR/2001: Study Treatment to Low Risk ALL
NCT00526175CI-TRIAL-00020586completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is increase the efficacy of consolidation (C1) after an intensification phase with high dose of methotrexate, applying analysis of minimal residual disease
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (9)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Cytosine Arabinoside | Drug | Cytarabine | ALIAS |
| Daunorubicin | Drug | Daunorubicin | ALIAS |
| L-Asparaginase | Drug | Asparaginase | ALIAS |
| Mercaptopurine | Drug | Mercaptopurine | ALIAS |
| Methotrexate | Drug | Methotrexate | ALIAS |
| Prednisone | Drug | Prednisone | ALIAS |
| Vincristine | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the efficacy of treatment in order to response rate, relapse free survival and global survival
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 15 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnoses of low risk acute lymphoblastic leukemia in children no treated previously Exclusion Criteria: * Mature B-ALL (FABL3) or with cytogenetic ALL "Burkitt-like" alterations (t\[8;14\], t\[2;8\], t\[8;22\]) * Mixed forms of ALL * Acute Leukemia no differentiate * Patients with coronary disorders, valvular or hypertensive cardiopathy * Patients with chronic liver disorders * Chronic pulmonary disorders * Renal insufficiency * Neurologic disfunctions * ECOG 3 and 4 * No signed consent form
References
Publications (0)
Data not yet available
No reference posted for this study.